Bruno Spire

Bruno Spire

Auto-generated profile, based on publicly available information

Bruno Spire

Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé et Traitement de l'Information Médicale, Marseille, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in International Journal of Drug Policy
Verified
Journal Article
Closed access
BSBruno Spire
Bruno Spire
GLGregory M. Lucas
Gregory M. Lucas
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri

1 October 2007 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
FMFabienne MARCELLIN
Fabienne MARCELLIN
MPMarie Préau
Marie Préau
IRIsabelle Ravaux
Isabelle Ravaux
PDPierre Dellamonica
Pierre Dellamonica
BSBruno Spire
Bruno Spire
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
To analyze the impact of self-reported fatigue and depressive symptoms on the quality of life (QOL) of patients co-infected with HIV and hepatitis C virus (HCV) not receiving anti-HCV therapy. We used data from a cross-sectional survey conducted among 115 co-infected adults including an assessment of QOL (WHOQOL-HIV bref questionnaire), depressive symptomatology (Center for Epidemiological Studies Depression Scale [CES-D]), and fatigue (Fatigue Impact Scale [FIS]). Eighty-four percent of patients had been infected through injecting drug use (IDU). Half reported a history of depression or other psychiatric co-morbidities, 57% presented depressive symptoms, and 69% reported fatigue. FIS and CES-D scores accounted for 54% and 66% of total variance in psychological QOL and level of independence-related QOL, respectively, in a multivariate analysis adjusted for sociodemographic and clinical characteristics and alcohol or drug use. High FIS scores were independently associated with impaired physical QOL and social relationships, whereas high CES-D scores were independently associated with lower environmental QOL. Self-reported fatigue and depressive symptoms are the best indicators of co-infected patients' QOL. These two indicators could be more easily used for a better clinical management of co-infected patients and also introduced as patient outcome measures in clinical research.

1 July 2004 in AIDS Care
Verified
Journal Article
Closed access
BSB. Spire
B. Spire
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
MGM.-A. Garzot
M.-A. Garzot
MLM. L'Henaff
M. L'Henaff
YOY. Obadia
Y. Obadia
TGThe Trt-5 Group
The Trt-5 Group
Efavirenz (EFV) is a potent antiretroviral drug; its use may be limited, however, by psychiatric symptoms that require its discontinuation. We sought to identify the characteristics that placed patients at an elevated risk of discontinuation. Data for this cross-sectional study came from a self-administered questionnaire distributed by French AIDS community associations; it collected information about sociodemographic characteristics, addictive behaviours, treatment regimens, EFV history and depression. Patients remaining on EFV for more than six months were compared with those who stopped taking it. Of the 828 patients who completed the questionnaire, 175 had taken EFV for at least six months, and 152 had discontinued it (median months [IQR] of exposure=4[2–10]). Of these 327 patients (median age=42), 23% were women, 46% were unemployed, 38% had a steady sexual partner and 24% reported a history of multiple depressive episodes. Logistic regression showed that the factors independently associated with EFV discontinuation were female gender (OR[95%CI]=2.2[1.2–3.8]), unemployment (1.8[1.1–2.8]), a steady sexual partner (1.7[1–2.5]) and multiple episodes of depression (2.6[1.5–4.5]). Clinicians should keep in mind the neuropsychiatric risks of EFV during the first year, especially among patients with a history of multiple depressive episodes.

1 July 2008 in Antiviral Therapy
Verified
Journal Article
Closed access
BSBruno Spire
Bruno Spire
MCMaria Patrizia Carrieri
Maria Patrizia Carrieri
PSPal Sopha
Pal Sopha
CPCamelia Protopopescu
Camelia Protopopescu
NPNarom Prak
Narom Prak
DLDidier Laureillard
Didier Laureillard
Background: The long-term maintenance of antiretroviral therapy (ART) remains an important issue, especially in limited-resource settings where additional barriers exist. A cross-sectional study was performed 24 months after ART initiation for patients treated in Cambodia in order to estimate the prevalence and identify determinants of non-adherence. Methods: Adults receiving ART for 24 ±2 months were considered eligible for the study. Self-reported non-adherence was defined according to an algorithm based on six items. The questionnaire also assessed ART-related side effects and HIV disclosure. HIV-1 RNA plasma viral load was measured using real-time PCR. Multivariate rare events logistic regression analysis was used to identify independent factors associated with non-adherence. Results: A total of 346 patients participated in the study. At 24 months, 95% of patients were adherent, 80% had HIV RNA 200 cells/mm 3 . Virological success was significantly higher in adherent patients than in non-adherent patients (81% versus 56%, P=0.021). Living in a rural area, limited HIV disclosure and perceived lipodystrophy were independently associated with non-adherence. Conclusions: At 24 months, adherence to ART was high and explained positive virological outcomes. In order to maintain adherence and long-term virological benefits, special attention should be given to patients living in rural areas, those with lipodystrophy-related symptoms and others who express difficulties disclosing their condition to close family members.

2 October 2017 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
LSLuis Sagaon-Teyssier
Luis Sagaon-Teyssier
BMBakridine Mmadi Mrenda
Bakridine Mmadi Mrenda
VKVohith Khol
Vohith Khol
LFLaurent Ferradini
Laurent Ferradini
SMSovatha Mam
Sovatha Mam
BSBruno Spire
Bruno Spire